Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether HIV-1-infected patients, who are
virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus
any third agent but are experiencing safety and/or tolerability issues, will maintain
virologic suppression after switching to a regimen of heat-stable ritonavir boosted
atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.